Tenaya therapeutics announces pricing of public offering

South san francisco, calif., nov. 17, 2022 (globe newswire) -- tenaya therapeutics, inc. (nasdaq: tnya), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the pricing of its underwritten public offering of 22,613,307 shares of its common stock at a price to the public of $2.60 per share and, to certain investors in lieu of common stock, pre-funded warrants to purchase up to an aggregate of 6,236,693 shares of its common stock at a purchase price of $2.599 per each pre-funded warrant, which represents the per share public offering price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant. all of the securities are to be sold by tenaya. in addition, tenaya has granted the underwriters a 30-day option to purchase up to an additional 4,327,500 shares of its common stock. before deducting the underwriting discounts and commissions and estimated offering expenses, tenaya expects to receive total gross proceeds of approximately $75 million, assuming no exercise of the underwriters' option to purchase additional shares. the offering is expected to close on or about november 21, 2022, subject to satisfaction of customary closing conditions.
TNYA Ratings Summary
TNYA Quant Ranking